Published online before print December 7, 2006, doi: 10.1161/01.RES.0000253900.66640.34
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Molecular Medicine |
Oxidative Stress–Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A–Associated Cardiac Cell Apoptosis
From Inserm U466 (D.P., A.D., O.C.), Toulouse; Inserm U388 (O.K., M.-H.S., A.P.), Toulouse; IFR 31 (D.C.), Service de Microchirurgie, Toulouse; Université Toulouse III Paul Sabatier (D.P., O.K., A.D., D.C., M.-H.S., A.P., O.C.); Cardiovascular and Thrombosis Department (N.L.), Sanofi-Aventis, Toulouse; and Université Paris-Sud (I.S.), Faculté de Pharmacie, Chatenay-Malabry, France. Current address for D.P., A.D., and O.C.: CNRS, Institut de Pharmacologie et de Biologie Structurale, UMR5089, Toulouse, France.
Correspondence to Dr Olivier Cuvillier, Inserm U466, BP 84225, 31432 Toulouse Cedex 4, France. E-mail olivier.cuvillier{at}ipbs.fr; and Dr Angelo Parini, Inserm U388, BP 84225, 31432 Toulouse Cedex 4, France. E-mail angelo.parini@toulouse.inserm.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The mitochondrial enzyme monoamine oxidase (MAO), its isoform MAO-A, plays a major role in reactive oxygen species–dependent cardiomyocyte apoptosis and postischemic cardiac damage. In the current study, we investigated whether sphingolipid metabolism can account for mediating MAO-A– and reactive oxygen species–dependent cardiomyocyte apoptosis. In H9c2 cardiomyoblasts, MAO-A–dependent reactive oxygen species generation led to mitochondria-mediated apoptosis, along with sphingosine kinase-1 (SphK1) inhibition. These phenomena were associated with generation of proapoptotic ceramide and decrease in prosurvival sphingosine 1-phosphate. These events were mimicked by inhibition of SphK1 with either pharmacological inhibitor or small interfering RNA, as well as by extracellular addition of C2-ceramide or H2O2. In contrast, enforced expression of SphK1 protected H9c2 cells from serotonin- or H2O2-induced apoptosis. Analysis of cardiac tissues from wild-type mice subjected to ischemia/reperfusion revealed significant upregulation of ceramide and inhibition of SphK1. It is noteworthy that SphK1 inhibition, ceramide accumulation, and concomitantly infarct size and cardiomyocyte apoptosis were significantly decreased in MAO-A–deficient animals. In conclusion, we show for the first time that the upregulation of ceramide/sphingosine 1-phosphate ratio is a critical event in MAO-A–mediated cardiac cell apoptosis. In addition, we provide the first evidence linking generation of reactive oxygen species with SphK1 inhibition. Finally, we propose sphingolipid metabolites as key mediators of postischemic/reperfusion cardiac injury.
Key Words: sphingosine kinase-1 • monoamine oxidases • ischemia/reperfusion • ROS • serotonin
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The ischemia/reperfusion (I/R) syndrome occurring during revascularization results in the progressive loss of cardiac myocytes, ultimately leading to heart failure.1
A wealth of reports indicate a pivotal role for apoptosis in cardiac myocyte death after I/R.2–4 Indeed, cardiomyocyte apoptosis was found during the early phase of reperfusion after myocardial ischemia in animal models5,6 and after cardiac transplantation in humans.7,8 In addition, prevention of apoptosis strongly reduced postischemic cardiac damage.
Abundant evidence suggests that reactive oxygen species (ROS) play an important role in the development and progression of postischemic myocardial damage, leading to apoptosis.9,10
The induction of oxidative stress is related to an activation of several enzymatic systems including monoamine oxidases (MAOs).11–13 MAOs catalyze oxidative deamination of several monoamines (eg, serotonin [5-hydroxytryptamine{5-HT}], noradrenaline, dopamine), resulting in significant ROS production.14 Based on their substrate preference and inhibitor specificity, 2 functional isoenzymes, MAO-A and MAO-B, have been identified.15 In the heart, MAO-A is a predominant enzyme involved in the deamination of endogenous or exogenous amines.16 Recently, we have shown that oxidative stress induced by MAO-A is responsible for receptor-independent, serotonin-mediated apoptosis during postischemic myocardial injury.17
Presently the link between MAO-produced ROS and apoptosis is not well defined. Promising candidates for mediating I/R-induced apoptosis are members of the sphingolipid family. Among these lipids, ceramide and sphingosine 1-phosphate (S1P) are potent messenger molecules playing opposite roles in cell fate.18 Whereas ceramide accumulation has been associated with cell growth arrest and apoptotic cell death, its downstream metabolite, S1P, is a growth promoter and survival factor (reviewed previously19). The dynamic balance between ceramide and S1P depends in part on the activity of sphingosine kinase-1 (SphK1), an enzyme playing an important role in cell survival.20 In heart, S1P has been shown to be involved in cardioprotection. Indeed, preincubation with S1P prevents the mortality induced by hypoxia in neonatal rat ventricular myocytes.21 In addition, SphK1 is upregulated during ischemic preconditioning and linked to enhanced myocardial survival.22 In contrast, ceramide signaling has been reported to be required for I/R-induced death of myocardial cells.23 Importantly, hypoxia/reoxygenation-induced ceramide generation was shown to rely on ROS production.24
Herein we report the involvement of the ceramide/S1P balance and SphK1 activity in MAO-A– and ROS-mediated apoptosis of H9c2 cardiomyoblasts, as well as in vivo during I/R-induced cardiac damage in MAO-A knockout (KO) and wild-type (WT) mice. Our results support the notion that SphK1 inhibition could be a central event in I/R cardiac injury.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Lines
The embryonic rat heart–derived myogenic cell line H9c2 was obtained from the American Type Culture Collection. These cells were cultured in DMEM, supplemented with 10% FCS and 4 mmol/L glutamine. Cells were grown at 37°C in an atmosphere of 5% CO2 and used below the 35th passage.
FLAG epitope–tagged WT human sphingosine kinase 1 (SphK1) cDNA (GenBank accession no. AF200328), subcloned into pcDNA3* vector25 was used for stable transfection by effectene reagent (Qiagen) in H9c2 cells. Mass pools of stable transfectants were selected in growth medium containing 1 mg/mL G418. Empty vector– and WT SphK1-transfected cells were designated H9c2/Neo and H9c2/SphK1 respectively. All experiments were conducted in the absence of serum at 50% confluence.
Materials
Culture medium, serum, and antibiotics were obtained from Invitrogen. Escherichia coli diacylglycerol kinase and n-octylglucoside were from Calbiochem. Alkaline phosphatase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and serotonin were from Sigma. Sphingosine kinase inhibitor (SKI) or 2-(p-hydroxy anilino)-4-(p-chlorophenyl)thiazole was from Calbiochem. C2-ceramide was from Biomol. [
-32P]-ATP (3000 mCi/mmol) was purchased from Perkin-Elmer, and silica gel 60 high-performance thin-layer chromatography (Partisil LK6D) plates were from Whatman International.
Cell Viability and Staining of Apoptotic Nuclei
Cell viability was measured using the MTT dye reduction assay as previously described.26 Apoptosis was assessed by double staining cells with Syto 13 (1 µmol/L) and propidium iodide (PI) (6 µg/mL) for 5 minutes at 37°C.27 Cells were then examined with a Leica fluorescent microscope, and apoptotic cells were characterized by condensed, fragmented nuclear regions.
Hydrogen Peroxide Production
Levels of intracellular hydrogen peroxide (H2O2) were determined spectrofluorometrically by the oxidation of the specific probe 2',7'-dichlorodihydrofluorescein diacetate (H2DCFHDA) (Molecular Probes) to 2',7'-7-dichlorofluorescein (DCF), as previously reported.28
Preparation of Mitochondria and Western Blot Analysis of Cytochrome c
Mitochondrial preparations were performed as previously described.29 In brief, cell samples were collected by centrifugation at 600g for 5 minutes at 4°C. The cell pellets were washed once with ice-cold PBS and resuspended with 5 volumes of ice-cold buffer A (20 mmol/L HEPES-KOH pH 7.5, 0.1% BSA, 1 mmol/L sodium EDTA, 1 mmol/L DTT, 0.1 mmol/L phenyl methanylsulfonyl fluoride, 20 µg/mL leupeptin, 10 µg/mL aprotinin, and 10 µg/mL pepstatin A) containing 250 mmol/L sucrose. After swelling on ice for 5 minutes, the cells were homogenized with 15 to 20 strokes of a no. 22 Kontes Dounce homogenizer with the B pestle, and the homogenates were centrifuged at 750g for 5 minutes at 4°C. The supernatants were then pelleted at 10 000g for 15 minutes at 4°C. Resulting pellets containing mitochondria were resuspended in cold buffer A. The supernatants were further cleared at 20 000g for 30 minutes at 4°C. For Western blot analysis, anti–cytochrome c monoclonal antibody (PharMingen) and anti–cytochrome oxidase subunit II monoclonal antibody (Molecular Probes) were used as primary antibodies. Proteins were visualized by ECL (Pierce) using anti-mouse or anti-rabbit horseradish peroxidase–conjugated IgG (Bio-Rad).
Western Blot Analysis of SphK1 Expression
Western blotting was performed as previously described.26 Rabbit anti-SphK1 (gift from Dr Stuart Pitson, Institute of Medical and Veterinary Science, Adelaide, Australia) and mouse 
-tubulin antibody (Sigma) were used as primary antibodies.
SphK1 Assay and Mass Measurements of Sphingolipids
SphK1 activity, ceramide and S1P levels were measured as previously described in detail.30
RNA Interference Experiments
Transient interference was achieved by double-stranded SphK1-specific small interfering RNA (siRNA) or scrambled siRNA.27 SiRNA transfection was performed according to the manufacturer’s instructions (Invitrogen). Briefly, 75 pmol/L siRNA were complexed with 1:125 final dilution of OligofectAMINE (Invitrogen) reagent and applied to 1.105 cells in a final volume of 250 µL of Opti-MEM (Invitrogen) without FCS or antibiotics. After incubation for 4 hour at 37°C under 5% CO2, 150 µL of DMEM with 30% FCS was added 20 hours later medium was changed to 1 mL DMEM with 10% FCS.
Preparation of Rat Ventricular Cardiomyocytes
Enriched cultures of neonatal (day 1 to 3) cardiomyocytes were prepared from hearts of Sprague-Dawley rats by a previously described enzymatic method.31 After treatment with collagenase type II (Sigma), and subsequent digestion with trypsin and deoxyribonuclease, cells were resuspended in complete medium (50% [vol/vol] DMEM, 50% [vol/vol] Ham’s F-12 medium, 1% nonessential amino acids, 2 mmol/L L-glutamine, penicillin [100 U/mL], streptomycin [100 µg/mL]) containing 10% FCS and incubated for 40 minutes at 37 C, allowing selective attachment of nonmyocytes. Cardiomyocyte-enriched suspensions were plated in complete medium containing 10% FCS. Each dish was incubated with complete serum-free medium (50% [vol/vol] DMEM, 50% [vol/vol] Ham’s F-12 medium, 1% BSA]) for 16 hours before experiment.
Animal Studies
We used 3-month-old males of the Tg8 strain of MAO-A KO mice and their WT C3H/HeOuJ controls. An insertional deletion in the Mao-a locus occurred following DNA injection into a 1-cell embryo of the C3H/HeOuJ inbred strain.32 The X-linked MAO-A mutation was maintained on the C3H/HeOuJ background by repeated backcrossing. In the current study, all subjects were generated from homozygous breeding pairs to avoid direct competition between mutant and WT pups, which is known to be detrimental to MAO-A–deficient pups (at risk of a 30% deficit in body weight). At the time of weaning, males were housed individually to prevent stress associated with the frequent fighting initiated by MAO-A KO mice. Mice were maintained on a 14 hours light/10 hours dark cycle, in a pathogen-free facility, and had free access to food and water. They were handled in accordance with the principles and procedures outlined in Council Directive 86/609/EEC (homozygous breeding is consistent with the commitment to reduce excess production of animals). Tg8 breeders were obtained from the French CNRS animal repository (CDTA, Orléans, France) and C3H/HeOuJ breeders were purchased from Charles River Laboratory.
The animals were anesthetized with an intraperitoneal injection of ketamine HCl 35 mg/kg and xylazine 5 mg/kg. A polyethylene tube size 90 was carefully inserted into the trachea, taped in place to prevent dislodgment, and connected via a loose junction to a small ventilator (model 683; Harvard Apparatus), set at a tidal volume and at a rate of 60 strokes per minute. Ligation of the left coronary artery was performed as previously described.17 After 30 minutes of ischemia, the ligature was released and the heart reperfused for 180 minutes. The protocol included different groups: mice subjected to 30 minutes of ischemia followed by 180 minutes of reperfusion and sham-operated animals, for both WT and MAO-A KO mice.
Determination of Area at Risk and Infarct Size
At the end of the infarction protocol, the ligature around the coronary artery was retightened and Evans blue dye (1.5%, 1.0 mL) was injected into the left ventricular cavity to measure the myocardial ischemic area at risk. The animals were euthanized immediately, and the heart was removed and then cut from apex to base into 4 to 5 transverse slices of equal thickness. The slices were then incubated in 1% triphenyltetrazolium chloride solution in isotonic pH 7.4 phosphate buffer at 37°C for 20 minutes. The slices were subsequently fixed in 10% formalin solution for 6 hours to assess myocardial tissue viability and determine myocardial infarct size. Red-stained viable tissue was easily distinguished from the infarcted pale/unstained necrotic tissue. The areas of infarcted tissue, the risk zone, and the whole left ventricle were determined by computer morphometry. The area for each region was averaged from slices. Infarct size was expressed as a percentage of the ischemic risk area.
Determination of Malondialdehyde Production
Malondialdehyde (MDA), an end product of lipid peroxidation, was determined by measurement of the chromogen generated from the reaction of MDA with 2-thiobarbituric acid, as described previously.17 Results are expressed as nanomole of MDA per milligram of protein.
Evaluation of Postischemic Apoptosis
DNA fragmentation was visualized in situ on formalin-fixed and paraffin-embedded sections by the terminal transferase-mediated dUTP nick-end labeling (TUNEL) procedure with the apoptosis detection kit of Promega (Madison, Wis). Briefly, deparaffinized sections were incubated in a 20 µg/mL proteinase K solution to permeabilize the tissues, then rinsed. The sections were incubated with 1 µL of terminal deoxynucleotidyl transferase (25 U/µL) and fluorescein-12-dUTP in equilibration buffer (25 mmol/L Tris-HCl [pH 6.6], 200 mmol/L potassium cacodylate [pH 6.6], 2.5 mmol/L cobalt chloride, 0.25 mg/mL BSA, 0.2 mmol/L DTT) for 1 hour at 37°C. Then, after rinsing in saline sodium citrate and PBS, the slides were immersed in 40 mL of PI solution (1 µg/µL) for 15 minutes. The positive control was treated by DNAse I (1 µg/µL) before being processed with the TUNEL procedure.
Caspase-3 Activity
The activity of caspase-3 was determined by using the fluorescence substrate Ac-DEVD-AMC (Bachem). The frozen kidney cortices were homogenized with 10 mmol/L HEPES (pH 7.4) containing 0.5% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate, 42 mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L DTT, 1 mmol/L phenyl methanylsulfonyl fluoride, 2 µg/mL leupeptin, and 1 µg/mL pepstatin A. The homogenate was then centrifuged at 10 000g for 10 minutes. Supernatant (containing 250 µg of total protein) was incubated with 40 µmol/L of Ac-DEVD-AMC for 60 minutes at 37°C. Fluorescent AMC (7-amino-4-methyl-coumarin) product formation was quantified at an excitation wavelength of 380 nm and emission of 460 nm using a fluorometer.26
Troponin Measurement
Plasma troponin I was measured by a quantitative rapid assay using the Cardiac Reader (Roche Diagnostics).
Statistical Analysis
The statistical significance of differences between the mean values was evaluated by unpaired Student’s t test. All statistical tests were 2-sided and the level of significance was set at P<0.05. Calculations were performed using Instat (GraphPad Software).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Serotonin Induces H9c2 Cells and Neonatal Cardiomyocytes Apoptosis, Which Is Mediated by SphK1 Inhibition and Upregulation of the Ceramide/S1P Ratio
The experiments were first performed in H9c2 cells, which predominantly express the MAO-A isoenzyme (data not shown). H9c2 treated with increasing serotonin concentration displayed a dose-dependent decrease in cell viability, associated with 40% increase in H2O2 content (Figure 1B). Syto 13/PI staining demonstrated that serotonin-induced cell death could be attributed to apoptosis (Figure 1C). Western blot analysis revealed that H9c2 apoptosis was concomitant to cytochrome c release from mitochondria (Figure 1D). All of these effects were prevented by both irreversible MAO inhibitor pargyline and N-acetyl-L-cysteine, an H2O2 scavenger (Figure 1A through 1D).
|
To determine the potential involvement of sphingolipid metabolism in cardiomyoblast apoptosis, we assessed H9c2 cells treated with serotonin for 16 hours for sphingolipid content and SphK1 activity. H9c2 apoptosis was associated with 
2-fold increase in intracellular ceramide (Figure 2A) and a significant decrease of intracellular S1P levels (Figure 2B). Similar to the onset of apoptosis, these effects were blocked by both pargyline and NAC. Thus, in H9c2 cells, serotonin treatment drastically modified the balance between ceramide and S1P toward proapoptotic ceramide, which resulted in a 3-fold increase in ceramide/S1P ratio. Concomitantly with S1P decrease, serotonin treatment resulted in approximately 40% inhibition of SphK1 activity (Figure 2C) and significant decrease in SphK1 protein level (Figure 2D). Importantly, both serotonin-induced shift of sphingolipid balance and SphK1 inhibition were abrogated by inhibition of MAOs or prevention of H2O2 accumulation.
|
Additional studies were conducted with neonatal rat cardiomyocytes to validate the data obtained in H9c2 cells. Serotonin induced modification of the sphingolipid biostat status. Ceramide content was indeed increased (Figure 3A) and S1P decreased (Figure 3B) after serotonin treatment. SphK1 activity was also markedly diminished (Figure 3C). Of note, these changes were inhibited by pargyline and NAC (Figure 3A through 3C).
|
SphK1 Inhibition or Addition of Ceramide Mimics Serotonin-Induced Apoptosis in H9c2
To validate the role of sphingolipid balance and SphK1 activity with regard to cell viability, we treated H9c2 cells with permeant C2-ceramide, siRNA to SphK1, and a pharmacological inhibitor of SphK1 (SKI). All treatments led to decreases in cell viability (Figure 4A) that could be attributed to apoptosis (Figure 5A). Pharmacological inhibition of SphK1 (Figure 4B) by SKI resulted in drastic changes in the sphingolipid balance, giving rise to the proportional decrease in the intracellular S1P and concomitant increase in ceramide (Figure 4C).
|
|
SphK1 Overexpression Renders H9c2 Resistant to Both Serotonin and SKI
To confirm the critical role of SphK1 inhibition in serotonin-induced apoptosis, we stably transfected H9c2 cells with SphK1 (H9c2/SphK1) and empty vector (H9c2/Neo). The average SphK1 activity in H9c2/neo cells was 158±11 pmol/mg protein per minute (similar to SphK1 activity of H9c2 parental cells), whereas a 20-fold increase in SphK1 activity (3071±118 pmol/mg protein per minute) was observed in H9c2/SphK1 cells. The increase in basal SphK1 activity in H9c2/SphK1 cells resulted in an augmentation of basal intracellular S1P content (from 20.05±2.26 pmol/mg protein to 27.69±2.06 pmol/mg protein) and a concomitant decrease in basal levels of ceramide (from 2.58±0.14 pmol/µg protein to 2.05±0.07 pmol/µg protein). Unlike empty vector–transfected cells, H9c2/SphK1 cells exhibited a significant resistance to apoptosis induced by serotonin, C2-ceramide, SKI, or siRNA to SphK1 (Figure 5A and 5B). This increased resistance was associated with a smaller values of ceramide/S1P ratio after treatment with serotonin or SKI in H9c2/SphK1 cells in comparison with H9c2/Neo cells (Figure 5D and 5E). Indeed, a 3-fold increase in ceramide/S1P ratio was found with serotonin-treated H9c2/Neo cells, as compared with a 1.7-fold increase with SphK1-overexpressing cells (calculated from the relative amounts of ceramide and S1P shown in Figure 5D and 5E, respectively; 1.89:0.61 versus 1.34:0.80). In a similar fashion, SKI treatment led to a 6.5-fold increase of ceramide/S1P ratio (2.14:0.33) in H9c2/Neo cells versus a 2.4-fold increase (1.81:0.75) in only H9c2/SphK1 cells. These smaller values of ceramide/S1P ratio in H9c2/SphK1 cells were provisioned by sustained SphK1 activity in response to serotonin and SKI (91% and 70%, respectively) in contrast to 64% and 31%, respectively, in H9c2/Neo cells (Figure 5C).
H2O2 Treatment Leads to SphK1 Downregulation
After establishing that serotonin-induced SphK1 downregulation was inhibited by antioxidant, it was of interest to assess whether addition of exogenous H2O2 could mimic the effect of serotonin on SphK1 activity. As shown in Figure 6A, addition of H2O2 led to a very strong inhibition of SphK1 activity. This was further illustrated by decrease in S1P content (Figure 6A, inset). Of note, pretreatment with NAC could totally impede SphK1 inhibition and S1P level decline induced by addition of H2O2 (Figure 6A). We next investigated the role of SphK1 in regulating H2O2 intracellular levels and apoptosis after H2O2 treatment. Although SphK1 overexpression did not lower the content of H2O2 (Figure 6B), it did block the loss of cell viability of H9c2 cells treated by H2O2 (Figure 6C). As anticipated, pretreatment with NAC could lower the intracellular content of H2O2 and cell death triggered by exogenously added H2O2 (Figure 6B and 6C). These findings support the notion that H2O2 is an important regulator of SphK1 activity.
|
Cardioprotection of MAO-A KO Mice Is Associated With a Decrease in Production of ROS and Ceramide and an Increase in SphK1 Activity
To determine the relationship between sphingolipid signaling and MAO-mediated I/R-induced injury, we used a strain of MAO-A–deficient mice (MAO-A KO) and compared them with the WT strain. Both groups were subjected to 30 minutes of ischemia, followed by 180 minutes reperfusion and were then analyzed for various parameters. Myocardial infarct size was assessed as a percentage of the area at risk and was markedly reduced in the hearts of MAO-A–/– animals compared with WT (Figure 7A). In addition, the level of troponin I, a biomarker of cardiac injury after reperfusion, was significantly elevated in WT animal sera compared with MAO-A KO animals (Figure 7B). TUNEL staining of MAO-A KO and WT hearts subjected to I/R revealed that I/R induced a significant increase in the number of TUNEL-positive cells in WT hearts, whereas postreperfusion apoptotic lesions were strongly prevented in MAO-A KO hearts (Figure 7C). Concomitantly, caspase-3 activity was lower in the MAO-A KO hearts than in WT hearts (Figure 7D). The level of MDA, a marker of lipid peroxidation, in ventricles of MAO-A KO mice after 1 hour of reperfusion was significantly lower when compared with WT mice (Figure 8A).
|
|
Similar to the in vitro observations, analysis of heart tissues revealed a significant increase in the level of proapoptotic ceramide following ROS production (Figure 8B). Ceramide level detected in the postreperfusion hearts was significantly higher in the WT mice compared with MAO-A KO mice (Figure 8B). On the contrary, the postreperfusion level of SphK1 activity was much higher in hearts of MAO-A KO mice compared with WT mice (Figure 8C).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Herein we report for the first time that inhibition of SphK1 activity and change of the ceramide/S1P sphingolipid balance are key events in MAO-mediated cardiomyocyte apoptosis.
Accumulation of ROS is an early and well-established step in apoptotic cascades induced by I/R.9,10 One of the sources of ROS production during I/R are MAOs, the enzymes responsible for the metabolic degradation of serotonin, noradrenaline, and dopamine. Serotonin-derived ROS has been shown to play an important role in I/R-associated events, such as myocardial dysfunction.11–13 We have recently reported that oxidative stress induced by MAO-A is accountable for receptor-independent, serotonin-mediated apoptosis during postischemic myocardial injury.17
I/R-induced apoptosis has also been associated with accumulation of the proapoptotic sphingolipid ceramide,23,24,33 an event shown to be ROS dependent.24 Currently we demonstrate that ceramide increase induced by serotonin in H9c2 cells relies on MAO-A–induced ROS generation. Indeed this increase could be completely abolished by both inhibition of MAO activity and antioxidant treatment.
More importantly, we link, for the first time, the production of proapoptotic ROS not only with the ceramide increase but also with the fall in the intracellular antiapoptotic S1P content caused by a decline of SphK1 protein and activity. So far, such SphK1 loss has been reported in only cancer cells undergoing apoptosis in response to chemotherapeutic drugs.27,30,34 As proof of the strategic role for SphK1/S1P signaling, our studies showed that SphK1 overexpression markedly inhibited ROS-mediated, serotonin-induced cardiomyoblast apoptosis. Enforced SphK1 expression reduced ceramide elevation (triggered by serotonin) by driving ceramide metabolism toward the synthesis of S1P, known to oppose ceramide-induced proapoptotic effects.18 We further confirmed the specific function of SphK1 by showing first that siRNA against hSphK1 induced a strong loss of cell viability, thus suggesting that SphK1 activity was required for cell survival and that its attenuation was an important factor in cardiomyoblasts cell death. Second, the pharmacological inhibition of SphK1 was able to induce H9c2 cell death, notably by tilting the ceramide/S1P biostat toward ceramide accumulation.
Importantly, in H9c2 cells, SphK1/S1P signaling appears to lie downstream of MAOs and ROS. First, both inhibitor of MAO activity and antioxidant successfully blocked serotonin-induced SphK1 inhibition. Second, we showed that independent ROS production by H2O2 led to a dramatic decrease in SphK1 activity and S1P levels in H9c2 cells, events that could be totally hampered by NAC antioxidant. This finding reveals the general ability of ROS increase to trigger SphK1 inhibition. It is noteworthy that SphK1 treatment could protect against H2O2-induced cell death in a manner similar to that of serotonin overexpression.
Finally, our studies show that in vitro findings could be translated in vivo by using a MAO-A KO mouse model that is protected from I/R-induced cardiac damage. The protection of MAO-A knockouts was related to significantly lower ROS generation following I/R, and, similar to our in vitro findings, inhibition of MAO-mediated ROS resulted in abrogation of I/R-induced ceramide increase and SphK1 inhibition. Our results suggest that endogenous MAO-A–mediated ROS production is necessary for tipping the ceramide/S1P balance toward proapoptotic ceramide. Our results are supported by data from Jin et al, who showed that SphK1 activity was critical for ischemic preconditioning-induced cardioprotection, which could be abrogated by SphK1 inhibition.22
In conclusion, we propose a novel pathway linking MAO-A–generated ROS production and ceramide/S1P balance biostat in cardiac cells. We demonstrate, for the first time, that generation of ROS may result in SphK1 inhibition and, thus, in modification of sphingolipid biostat, which is a critical event in apoptosis progression. We propose that SphK1 might play an important role in post-I/R syndrome and, thus, present a potential as a target for anti-I/R therapies.
|
Acknowledgments |
|---|
Sources of Funding
Supported by the Institut National de la Santé et de la Recherche Médicale (INSERM). D.P. was supported by a postdoctoral fellowship from Association Etudes et Recherches Urologiques. O.K. was supported by a postdoctoral fellowship from the Fondation pour la Recherche Médicale (FRM). A.D. is a recipient of the Ministère de l’Enseignement Supérieur et de la Recherche.
Disclosures
None.
|
Footnotes |
|---|
*Both authors contributed equally to this work.
**Both authors contributed equally to this work.
Original received June 12, 2006; revision received November 15, 2006; accepted November 16, 2006.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Sabbah HN, Sharov VG, Goldstein S. Cell death, tissue hypoxia and the progression of heart failure. Heart Fail Rev. 2000; 5: 131–138.[CrossRef][Medline] [Order article via Infotrieve]
2. Saitoh T, Nakajima T, Takahashi T, Kawahara K. Changes in cardiovascular function on treatment of inhibitors of apoptotic signal transduction pathways in left ventricular remodeling after myocardial infarction. Cardiovasc Pathol. 2006; 15: 130–138.[CrossRef][Medline] [Order article via Infotrieve]
3. van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005; 67: 21–29.
4. Kitsis RN, Mann DL. Apoptosis and the heart: a decade of progress. J Mol Cell Cardiol. 2005; 38: 1–2.[CrossRef][Medline] [Order article via Infotrieve]
5. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. Oct. 1994; 94: 1621–1628.[Medline] [Order article via Infotrieve]
6. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 1996; 79: 949–956.
7. de Groot-Kruseman HA, Baan CC, Zondervan PE, de Weger RA, Niesters HG, Balk AH, Weimar W. Apoptotic death of infiltrating cells in human cardiac allografts is regulated by IL-2, FASL, and FLIP. Transplant Proc. 2004; 36: 3143–3148.[CrossRef][Medline] [Order article via Infotrieve]
8. Lesauskaite V, Epistolato MC, Ivanoviene L, Tanganelli P. Apoptosis of cardiomyocytes in explanted and transplanted hearts. Comparison of results from in situ TUNEL, ISEL, and ISOL reactions. Am J Clin Pathol. 2004; 121: 108–116.[CrossRef][Medline] [Order article via Infotrieve]
9. Bolli R. Basic and clinical aspects of myocardial stunning. Prog Cardiovasc Dis. 1998; 40: 477–516.[CrossRef][Medline] [Order article via Infotrieve]
10. Bandyopadhyay D, Chattopadhyay A, Ghosh G, Datta AG. Oxidative stress-induced ischemic heart disease: protection by antioxidants. Curr Med Chem. 2004; 11: 369–387.[CrossRef][Medline] [Order article via Infotrieve]
11. Kunduzova OR, Bianchi P, Parini A, Cambon C. Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion. Eur J Pharmacol. 2002; 448: 225–230.[CrossRef][Medline] [Order article via Infotrieve]
12. Maurel A, Hernandez C, Kunduzova O, Bompart G, Cambon C, Parini A, Frances B. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol. 2003; 284: H1460–H1467.
13. Babior BM. NADPH oxidase: an update. Blood. 1999; 93: 1464–1476.
14. Weyler W, Hsu YP, Breakefield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther. 1990; 47: 391–417.[CrossRef][Medline] [Order article via Infotrieve]
15. Youdim MB, Finberg JP. New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem Pharmacol. 1991; 41: 155–162.[CrossRef][Medline] [Order article via Infotrieve]
16. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002; 34: 379–388.[CrossRef][Medline] [Order article via Infotrieve]
17. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, Seguelas MH, Nistri S, Colucci W, Leducq N, Parini A. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation. 2005; 112: 3297–3305.
18. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996; 381: 800–803.[CrossRef][Medline] [Order article via Infotrieve]
19. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003; 4: 397–407.[CrossRef][Medline] [Order article via Infotrieve]
20. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, Spiegel S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol. 1999; 147: 545–558.
21. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 2001; 33: 1713–1717.[CrossRef][Medline] [Order article via Infotrieve]
22. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation. 2004; 110: 1980–1989.
23. Bielawska AE, Shapiro JP, Jiang L, Melkonyan HS, Piot C, Wolfe CL, Tomei LD, Hannun YA, Umansky SR. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol. 1997; 151: 1257–1263.[Abstract]
24. Hernandez OM, Discher DJ, Bishopric NH, Webster KA. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res. 2000; 86: 198–204.
25. Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA, D’Andrea RJ, Wattenberg BW. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem. 2000; 275: 33945–33950.
26. Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J Biol Chem. 1998; 273: 2910–2916.
27. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B, Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005; 65: 11667–11675.
28. Bianchi P, Pimentel DR, Murphy MP, Colucci WS, Parini A. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J. 2005; 19: 641–643.
29. Cuvillier O, Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood. 2001; 98: 2828–2836.
30. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 2006; 20: 95–102.[CrossRef][Medline] [Order article via Infotrieve]
31. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 1996; 137: 4145–4153.[Abstract]
32. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Muller U, Aguet M, Babinet C, Shih JC, De Maeyer ED. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science. 1995; 268: 1763–1766.
33. Argaud L, Prigent AF, Chalabreysse L, Loufouat J, Lagarde M, Ovize M. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2004; 286: H246–H251.
34. Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, Dbaibo GS, Hannun YA, Obeid LM. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem. 2004; 279: 20546–20554.
This article has been cited by other articles:
 |
|
 |
|
  C. Villeneuve, A. Caudrillier, C. Ordener, N. Pizzinat, A. Parini, and J. Mialet-Perez Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H821 - H828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Roberts, A. L. Clark, and K. K. Witte Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease -- do we need to screen our patients? Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 153 - 163. [Abstract] [PDF]
|
|
|
|
|
|
A. N. Kavazis, S. Alvarez, E. Talbert, Y. Lee, and S. K. Powers Exercise training induces a cardioprotective phenotype and alterations in cardiac subsarcolemmal and intermyofibrillar mitochondrial proteins Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H144 - H152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ader, B. Malavaud, and O. Cuvillier When the Sphingosine Kinase 1/Sphingosine 1-Phosphate Pathway Meets Hypoxia Signaling: New Targets for Cancer Therapy Cancer Res., May 1, 2009; 69(9): 3723 - 3726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Karliner Sphingosine kinase regulation and cardioprotection Cardiovasc Res, May 1, 2009; 82(2): 184 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Skoura and T. Hla Regulation of vascular physiology and pathology by the S1P2 receptor subtype Cardiovasc Res, May 1, 2009; 82(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ader, L. Brizuela, P. Bouquerel, B. Malavaud, and O. Cuvillier Sphingosine Kinase 1: A New Modulator of Hypoxia Inducible Factor 1{alpha} during Hypoxia in Human Cancer Cells Cancer Res., October 15, 2008; 68(20): 8635 - 8642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takabe, S. W. Paugh, S. Milstien, and S. Spiegel "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets Pharmacol. Rev., June 1, 2008; 60(2): 181 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, N. Honbo, E. J. Goetzl, K. Chatterjee, J. S. Karliner, and M. O. Gray Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3150 - H3158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Jin, J. Zhang, Y. Huang, H. E. Hoover, D. A. Vessey, and J. S. Karliner A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury Cardiovasc Res, October 1, 2007; 76(1): 41 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gomez-Brouchet, D. Pchejetski, L. Brizuela, V. Garcia, M.-F. Altie, M.-L. Maddelein, M.-B. Delisle, and O. Cuvillier Critical Role for Sphingosine Kinase-1 in Regulating Survival of Neuroblastoma Cells Exposed to Amyloid-beta Peptide Mol. Pharmacol., August 1, 2007; 72(2): 341 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang Chasing sphingosine-1-phosphate, a lipid mediator for cardiomyocyte survival Cardiovasc Res, April 1, 2007; 74(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
R. Tao, J. Zhang, D. A. Vessey, N. Honbo, and J. S. Karliner Deletion of the Sphingosine Kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes Cardiovasc Res, April 1, 2007; 74(1): 56 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maceyka, S. Milstien, and S. Spiegel Shooting the Messenger: Oxidative Stress Regulates Sphingosine-1-Phosphate Circ. Res., January 5, 2007; 100(1): 7 - 9. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||